Investor Relations

2018 Press Releases

Receive E-mail AlertsE-mail Alerts
RSS RSS Feeds
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
09/26/18Vanda Pharmaceuticals Announces Participation at Oppenheimer and Cantor Fitzgerald Fall 2018 Investor ConferencesPrinter Friendly Version
09/20/18Vanda Announces Listing of a New HETLIOZ® Patent in the FDA Orange BookPrinter Friendly Version
09/12/18HETLIOZ® (Tasimelteon) Driving Study Demonstrates No Impairment in Next Morning PerformancePrinter Friendly Version
09/04/18Vanda Pharmaceuticals Announces Participation at September 2018 Investor ConferencesPrinter Friendly Version
08/14/18Vanda Wins Denial of Petition For Rehearing on Fanapt®Printer Friendly Version
08/13/18Vanda Pharmaceuticals Announces the Appointment of General CounselPrinter Friendly Version
08/01/18Vanda Pharmaceuticals Reports Second Quarter 2018 Financial ResultsPrinter Friendly Version
07/17/18Vanda Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 1, 2018Printer Friendly Version
06/01/18Vanda Pharmaceuticals Announces Participation at June 2018 Investor ConferencesPrinter Friendly Version
05/23/18HETLIOZ® (tasimelteon) Effective in Treating Jet Lag during Transatlantic TravelPrinter Friendly Version
05/07/18Vanda Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care ConferencePrinter Friendly Version
05/02/18Vanda Pharmaceuticals Reports First Quarter 2018 Financial ResultsPrinter Friendly Version
04/18/18Vanda Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 2, 2018Printer Friendly Version
04/13/18Vanda Wins Appeal Case on Fanapt®Printer Friendly Version
04/09/18Vanda to Present Tradipitant Scientific Posters at the 10th Georg Rajka International Symposium of Atopic DermatitisPrinter Friendly Version
03/15/18Vanda Pharmaceuticals Inc. Prices Public Offering of Common StockPrinter Friendly Version
03/14/18Vanda Pharmaceuticals Inc. Proposes Public Offering of Common StockPrinter Friendly Version
03/06/18Vanda Pharmaceuticals Announces Participation at March 2018 Investor ConferencesPrinter Friendly Version
03/05/18HETLIOZ® (tasimelteon) Demonstrates Efficacy to Treat Jet Lag Disorder in an 8 Hour Phase Advance Clinical StudyPrinter Friendly Version
02/14/18Vanda Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial ResultsPrinter Friendly Version
01/30/18Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 14, 2018Printer Friendly Version
01/07/18Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2017 Revenue Results and 2018 GuidancePrinter Friendly Version
  
Home | About Vanda | Product Pipeline| Partnering | Investor Relations | News | Careers | Contact Us
Copyright © 2005-2017 Vanda Pharmaceuticals | Terms & Conditions | Privacy Policy